Current understanding of the role of microRNAs in spinocerebellar ataxias

Cerebellum and Ataxias

Volumn 1, Issue 1, 2014, Pages

  Koscianska, Edyta ^a   Krzyzosiak, Wlodzimierz J ^a  

^a POLISH ACADEMY OF SCIENCES   (Poland)

Author keywords

Ataxin; Luciferase assay; MiRNA; PolyQ expansion; Target validation; TREDs

Indexed keywords

ATAXIN 1; ATAXIN 3; MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 125B; MICRORNA 13A; MICRORNA 144; MICRORNA 146A; MICRORNA 150; MICRORNA 181A 1; MICRORNA 19A; MICRORNA 25; MICRORNA 302; MICRORNA 33; MICRORNA 335; MICRORNA 34; MICRORNA 34B; MICRORNA 375; MICRORNA 9 2; MICRORNA 92; MICRORNA 92A; RENILLA LUCIFERIN 2 MONOOXYGENASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ATXN1 GENE; ATXN3 GENE; CAG REPEAT; DISEASE COURSE; DOWN REGULATION; ENDOCYTOSIS; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; MACHADO JOSEPH DISEASE; MICROARRAY ANALYSIS; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN RNA BINDING; REGULATORY RNA SEQUENCE; REVIEW; RISK FACTOR; RNA METABOLISM; SPINOCEREBELLAR ATAXIA TYPE 1; SPINOCEREBELLAR ATAXIA TYPE 17; SPINOCEREBELLAR ATAXIA TYPE 2; SPINOCEREBELLAR ATAXIA TYPE 6; SPINOCEREBELLAR ATAXIA TYPE 7; SPINOCEREBELLAR DEGENERATION; TRANSCRIPTION REGULATION; TRINUCLEOTIDE REPEAT; UPREGULATION;

EID: 85007537337     PISSN: None     EISSN: 20538871     Source Type: Journal    
DOI: 10.1186/2053-8871-1-7     Document Type: Review

References (91)

1. Gatchel JR, Zoghbi HY: Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 2005,6(10):743-755.
2. Orr HT: Cell biology of spinocerebellar ataxia. J Cell Biol 2012,197(2):167-177.
3. Orr HT, Zoghbi HY: Trinucleotide repeat disorders. Annu Rev Neurosci 2007, 30: 575-621.
4. Matilla-Duenas A, Ashizawa T, Brice A, Magri S, McFarland KN, Pandolfo M, Pulst SM, Riess O, Rubinsztein DC, Schmidt J, Schmidt T, Scoles DR, Stevanin G, Taroni F, Underwood BR, Sanchez I: Consensus Paper: Pathological Mechanisms Underlying Neurodegeneration in Spinocerebellar Ataxias. Cerebellum 2013,13(2):269-302.
5. Matilla-Duenas A, Goold R, Giunti P: Clinical, genetic, molecular, and pathophysiological insights into spinocerebellar ataxia type 1. Cerebellum 2008,7(2):106-114.
6. Orr HT, Chung MY, Banfi S, Kwiatkowski TJ Jr, Servadio A, Beaudet AL, McCall AE, Duvick LA, Ranum LP, Zoghbi HY: Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993,4(3):221-226.
7. David G, Abbas N, Stevanin G, Durr A, Yvert G, Cancel G, Weber C, Imbert G, Saudou F, Antoniou E, Drabkin H, Gemmill R, Giunti P, Benomar A, Wood N, Ruberg M, Agid Y, Mandel JL, Brice A: Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997,17(1):65-70.
8. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier JM, Weber C, Mandel JL, Cancel G, Abbas N, Durr A, Didierjean O, Stevanin G, Agid Y, Brice A: Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996,14(3):285-291.
9. Pulst SM, Nechiporuk A, Nechiporuk T, Gispert S, Chen XN, Lopes-Cendes I, Pearlman S, Starkman S, Orozco-Diaz G, Lunkes A, DeJong P, Rouleau GA, Auburger G, Korenberg JR, Figueroa C, Sahba S: Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996,14(3):269-276.
10. Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, Kawakami H, Nakamura S, Nishimura M, Akiguchi , Kimura J, Narumiya S, Kakizuka A: CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994,8(3):221-228.
11. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, Dobyns WB, Subramony SH, Zoghbi HY, Lee CC: Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997,15(1):62-69.
12. Nakamura K, Jeong SY, Uchihara T, Anno M, Nagashima K, Nagashima T, Ikeda S, Tsuji S, Kanazawa I: SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001,10(14):1441-1448.
13. Mirkin SM: Expandable DNA, repeats and human disease. Nature 2007,447(7147):932-940.
14. Lopez Castel A, Cleary JD, Pearson CE: Repeat instability as the basis for human diseases and as a potential target for therapy. Nat Rev Mol Cell Biol 2010,11(3):165-170.
15. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP: Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997,90(3):537-548.
16. Birman S: Neurodegeneration: RNA turns number one suspect in polyglutamine diseases. Curr Biol 2008,18(15):R659-R661.
17. Li LB, Bonini NM: Roles of trinucleotide-repeat RNA in neurological disease and degeneration. Trends Neurosci 2010,33(6):292-298.
18. Fiszer A, Krzyzosiak WJ: RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J Mol Med (Berl) 2013,91(6):683-691.
19. Marti E, Estivill X: Small non-coding RNAs add complexity to the RNA pathogenic mechanisms in trinucleotide repeat expansion diseases. Front Mol Neurosci 2013, 6: 45.
20. Griffiths-Jones S, Saini HK, Van Dongen S, Enright AJ: miRBase: tools for microRNA genomics. Nucleic Acids Res 2008, 36: D154-D158.
21. Chekulaeva M, Filipowicz W: Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 2009,21(3):452-460.
22. Kim VN, Han J, Siomi MC: Biogenesis of small RNAs in animals. Nat Rev Mol Cell Biol 2009,10(2):126-139.
23. Krol J, Loedige I, Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010,11(9):597-610.
24. Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009,11(3):228-234.
25. Starega-Roslan J, Koscianska E, Kozlowski P, Krzyzosiak WJ: The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci 2011,68(17):2859-2871.
26. Stroynowska-Czerwinska A, Fiszer A, Krzyzosiak WJ: The panorama of miRNA-mediated mechanisms in mammalian cells. Cell Mol Life Sci 2014,71(12):2253-2270.
27. Burright EN, Clark HB, Servadio A, Matilla T, Feddersen RM, Yunis WS, Duvick LA, Zoghbi HY, Orr HT: SCA1 transgenic mice: a model for neurodegeneration caused by an expanded CAG trinucleotide repeat. Cell 1995,82(6):937-948.
28. Cemal CK, Carroll CJ, Lawrence L, Lowrie MB, Ruddle P, Al-Mahdawi S, King RH, Pook MA, Huxley C, Chamberlain S: YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 2002,11(9):1075-1094.
29. Huynh DP, Figueroa K, Hoang N, Pulst SM: Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 2000,26(1):44-50.
30. Xia H, Mao Q, Eliason SL, Harper SQ, Martins IH, Orr HT, Paulson HL, Yang L, Kotin RM, Davidson BL: RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004,10(8):816-820.
31. Barbato C, Ruberti F, Cogoni C: Searching for MIND: microRNAs in neurodegenerative diseases. J Biomed Biotechnol 2009, 2009: 871313.
32. Bushati N, Cohen SM: MicroRNAs in neurodegeneration. Curr Opin Neurobiol 2008,18(3):292-296.
33. Hebert SS, De Strooper B: Alterations of the microRNA network cause neurodegenerative disease. Trends Neurosci 2009,32(4):199-206.
34. Lau P, De Strooper B: Dysregulated microRNAs in neurodegenerative disorders. Semin Cell Dev Biol 2010,21(7):768-773.
35. Martino S, Di Girolamo I, Orlacchio A, Datti A: MicroRNA implications across neurodevelopment and neuropathology. J Biomed Biotechnol 2009, 2009: 654346.
36. Roshan R, Ghosh T, Scaria V, Pillai B: MicroRNAs: novel therapeutic targets in neurodegenerative diseases. Drug Discov Today 2009,14(23-24):1123-1129.
37. Schaefer A, O'Carroll D, Tan CL, Hillman D, Sugimori M, Llinas R, Greengard P: Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med 2007,204(7):1553-1558.
38. Weinberg MS, Wood MJ: Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics. Hum Mol Genet 2009,18(R1):R27-R39.
39. Eacker SM, Dawson TM, Dawson VL: The interplay of microRNA and neuronal activity in health and disease. Front Cell Neurosci 2013, 7: 136.
40. Sun AX, Crabtree GR, Yoo AS: MicroRNAs: regulators of neuronal fate. Curr Opin Cell Biol 2013,25(2):215-221.
41. Follert P, Cremer H, Beclin C: MicroRNAs in brain development and function: a matter of flexibility and stability. Front Mol Neurosci 2014, 7: 5.
42. Delay C, Mandemakers W, Hebert SS: MicroRNAs in Alzheimer's disease. Neurobiol Dis 2012,46(2):285-290.
43. Gascon E, Gao FB: Cause or Effect: Misregulation of microRNA Pathways in Neurodegeneration. Front Neurosci 2012, 6: 48.
44. Esteller M: Non-coding RNAs in human disease. Nat Rev Genet 2011,12(12):861-874.
45. Gehrke S, Imai Y, Sokol N, Lu B: Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010,466(7306):637-641.
46. Savas JN, Makusky A, Ottosen S, Baillat D, Then F, Krainc D, Shiekhattar R, Markey SP, Tanese N: Huntington's disease protein contributes to RNA-mediated gene silencing through association with Argonaute and P bodies. Proc Natl Acad Sci U S A 2008,105(31):10820-10825.
47. Koscianska E, Kozlowska E, Jaworska E, Krzyzosiak W: MicroRNA Deregulation in Trinucleotide Repeat Expansion Disorders. In Applied RNAi: From Fundamental Research to Therapeutic Applications. Edited by: Patrick A, Marc S. Weinberg: Caister Academic Press; 2014:227-246.
48. Lee Y, Samaco RC, Gatchel JR, Thaller C, Orr HT, Zoghbi HY: miR-19, miR-101 and miR-130 co-regulate ATXN1 levels to potentially modulate SCA1 pathogenesis. Nat Neurosci 2008,11(10):1137-1139.
49. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microRNA targets. Cell 2003,115(7):787-798.
50. Persengiev S, Kondova I, Otting N, Koeppen AH, Bontrop RE: Genome-wide analysis of miRNA expression reveals a potential role for miR-144 in brain aging and spinocerebellar ataxia pathogenesis. Neurobiol Aging 2011,32(12):2316 e17-27.
51. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007,39(5):673-677.
52. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 2005,435(7043):834-838.
53. Rodriguez-Lebron E, Liu G, Keiser M, Behlke MA, Davidson BL: Altered Purkinje cell miRNA expression and SCA1 pathogenesis. Neurobiol Dis 2013, 54: 456-463.
54. Keiser MS, Geoghegan JC, Boudreau RL, Lennox KA, Davidson BL: RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1. Neurobiol Dis 2013, 56: 6-13.
55. Reinhardt A, Feuillette S, Cassar M, Callens C, Thomassin H, Birman S, Lecourtois M, Antoniewski C, Tricoire H: Lack of miRNA Misregulation at Early Pathological Stages in Drosophila Neurodegenerative Disease Models. Front Genet 2012, 3: 226.
56. Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM: MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell 2006,24(1):157-163.
57. Liu N, Landreh M, Cao K, Abe M, Hendriks GJ, Kennerdell JR, Zhu Y, Wang LS, Bonini NM: The microRNA miR-34 modulates ageing and neurodegeneration in Drosophila. Nature 2012,482(7386):519-523.
58. Shi Y, Huang F, Tang B, Li J, Wang J, Shen L, Xia K, Jiang H: MicroRNA profiling in the serums of SCA3/MJD patients. Int J Neurosci 2013,124(2):97-101.
59. Cheever A, Blackwell E, Ceman S: Fragile X protein family member FXR1P is regulated by microRNAs. RNA 2010,16(8):1530-1539.
60. Gaughwin PM, Ciesla M, Lahiri N, Tabrizi SJ, Brundin P, Bjorkqvist M: Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum Mol Genet 2011,20(11):2225-2237.
61. Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ: Micro RNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Neurosci Lett 2010,476(1):18-22.
62. Roshan R, Ghosh T, Gadgil M, Pillai B: Regulation of BACE1 by miR-29a/b in a cellular model of Spinocerebellar Ataxia 17. RNA Biol 2012,9(6):891-899.
63. Shioya M, Obayashi S, Tabunoki H, Arima K, Saito Y, Ishida T, Satoh J: Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol Appl Neurobiol 2010,36(4):320-330.
64. Sinha M, Ghose J, Das E, Bhattarcharyya NP: Altered microRNAs in STHdh(Q111)/Hdh(Q111) cells: miR-146a targets TBP. Biochem Biophys Res Commun 2010,396(3):742-747.
65. McCann C, Holohan EE, Das S, Dervan A, Larkin A, Lee JA, Rodrigues V, Parker R, Ramaswami M: The Ataxin-2 protein is required for microRNA function and synapse-specific long-term olfactory habituation. Proc Natl Acad Sci U S A 2011,108(36):E655-E662.
66. Fiszer A, Krzyzosiak WJ: Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res 2014. Epub ahead of print.
67. Witkos TM, Koscianska E, Krzyzosiak WJ: Practical Aspects of microRNA Target Prediction. Curr Mol Med 2011,11(2):93-109.
68. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS: Human MicroRNA targets. PLoS Biol 2004,2(11):e363.
69. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA target predictions. Nat Genet 2005,37(5):495-500.
70. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005,120(1):15-20.
71. Kruger J, Rehmsmeier M: RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res 2006, 34: W451-W454.
72. Kertesz M, Iovino N, Unnerstall U, Gaul U, Segal E: The role of site accessibility in microRNA target recognition. Nat Genet 2007,39(10):1278-1284.
73. Rinck A, Preusse M, Laggerbauer B, Lickert H, Engelhardt S, Theis FJ: The human transcriptome is enriched for miRNA-binding sites located in cooperativity-permitting distance. RNA Biol 2013,10(7):1125-1135.
74. Incarnato D, Neri F, Diamanti D, Oliviero S: MREdictor: a two-step dynamic interaction model that accounts for mRNA accessibility and Pumilio binding accurately predicts microRNA targets. Nucleic Acids Res 2013,41(18):8421-8433.
75. Kuhn DE, Martin MM, Feldman DS, Terry AV Jr, Nuovo GJ, Elton TS: Experimental validation of miRNA targets. Methods 2008,44(1):47-54.
76. Thomson DW, Bracken CP, Goodall GJ: Experimental strategies for microRNA target identification. Nucleic Acids Res 2011,39(16):6845-6853.
77. Vasudevan S: Functional validation of microRNA-target RNA interactions. Methods 2012,58(2):126-134.
78. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP: miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006,3(2):87-98.
79. Liu Z, Sall A, Yang D: MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci 2008,9(6):978-999.
80. Wang X: Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucleic Acids Res 2006,34(5):1646-1652.
81. Ziegelbauer JM, Sullivan CS, Ganem D: Tandem array-based expression screens identify host mRNA targets of virus-encoded microRNAs. Nat Genet 2009,41(1):130-134.
82. Konig J, Zarnack K, Luscombe NM, Ule J: Protein-RNA interactions: new genomic technologies and perspectives. Nat Rev Genet 2011,13(2):77-83.
83. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I: A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006,126(6):1203-1217.
84. Nicolas FE: Experimental validation of microRNA targets using a luciferase reporter system. Methods Mol Biol 2011, 732: 139-152.
85. Hsu SD, Tseng YT, Shrestha S, Lin YL, Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, Jian TY, Lin FM, Chang TH, Weng SL, Liao KW, Liao IE, Liu CC, Huang HD: miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic Acids Res 2014, 42: D78-D85.
86. Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, Chien CH, Wu MC, Huang CY, Tsou AP, Huang HD: miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res 2011, 39: D163-D169.
87. Evers MM, Toonen LJ, Van Roon-Mom WM: Ataxin-3 Protein and RNA Toxicity in Spinocerebellar Ataxia Type 3: Current Insights and Emerging Therapeutic Strategies. Mol Neurobiol 2013,49(3):1513-1531.
88. Ranum LP, Lundgren JK, Schut LJ, Ahrens MJ, Perlman S, Aita J, Bird TD, Gomez C, Orr HT: Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am J Hum Genet 1995,57(3):603-608.
89. Zoghbi HY, Orr HT: Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem 2009,284(12):7425-7429.
90. Koscianska E, Baev V, Skreka K, Oikonomaki K, Rusinov V, Tabler M, Kalantidis K: Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol 2007, 8: 79.
91. Kozlowska E, Krzyzosiak WJ, Koscianska E: Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs. Int J Mol Sci 2013,14(8):16999-17016.